Enveric Biosciences Inc vs Under Armour Inc Class A — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Under Armour Inc Class A trades at $5.39 (market cap $2.57B). The key difference: Under Armour Inc Class A is far larger — about 414.5× Enveric Biosciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | UAA | |
|---|---|---|
Market Cap | $6.20M | $2.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $8.14 |
52-Week Low | $1.27 | $4.17 |
Enterprise Value | $1.30M | $3.55B |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Under Armour (UAA) trades at $6.11, down 4.38% today, reflecting ongoing challenges. The stock shows a bearish technical trend with key support at $6. Recent Q2 2026 earnings beat expectations with EPS of $0.05 versus $0.02, but revenue declined year-over-year. Financials reveal negative net income margin of -9.98% and weak cash flow, with net cash outflow of $361.87 million in 2025. Analysts maintain a cautious stance amid soft demand in key markets.
The outlook remains challenging due to persistent revenue declines and profitability issues. Investment opportunities hinge on successful execution of turnaround strategies, but risks include intense competition and macroeconomic pressures. With a consensus price target of $5.96 below the current price, Wall Street sentiment is neutral to bearish, emphasizing the need for improved fundamentals to drive recovery.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →